levofloxacin has been researched along with ceftobiprole in 7 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (ceftobiprole) | Trials (ceftobiprole) | Recent Studies (post-2010) (ceftobiprole) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 212 | 15 | 97 |
| Protein | Taxonomy | levofloxacin (IC50) | ceftobiprole (IC50) |
|---|---|---|---|
| MecA | Staphylococcus aureus | 4.1667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laohavaleeson, S; Nicolau, DP; Tessier, PR | 1 |
| Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Chen, H; Chen, M; Liu, Y; Ma, Y; Nichols, WW; Sun, W; Wang, H; Zhang, J; Zhao, C | 1 |
| Distèche-Nguyen, M; Gerards, T; Luxen, A; Miguet, L; Pasha, FA; Thomas, A; Zervosen, A | 1 |
| Davies, T; Decker-Burgard, S; Körber-Irrgang, B; Kresken, M; Läuffer, J | 1 |
1 trial(s) available for levofloxacin and ceftobiprole
| Article | Year |
|---|---|
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
6 other study(ies) available for levofloxacin and ceftobiprole
| Article | Year |
|---|---|
Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Disease Models, Animal; Drug Resistance, Bacterial; Female; Humans; Methicillin Resistance; Mice; Mice, Inbred BALB C; Phenotype; Pneumonia, Staphylococcal; Staphylococcus aureus | 2008 |
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
Topics: Anti-Bacterial Agents; China; Cities; Drug Resistance, Multiple, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Vancomycin; Vancomycin Resistance | 2009 |
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
Topics: Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ligands; Penicillin-Binding Proteins; Protein Binding; Streptococcus pneumoniae; Structure-Activity Relationship | 2009 |
In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Stem Cells; Time Factors | 2011 |